BCRX planning U.S. flu study for 2001/2002 season

BioCryst (BCRX) said that following discussions with the FDA, it will begin U.S. Phase III testing of its RWJ-270201 oral influenza neuraminidase inhibitor in the 2001/2002 flu season. Last year, BCRX said a North American Phase III trial of RWJ-270201 would not begin during the 2000/2001 season, as had been expected, after the FDA requested additional monitoring procedures that required an amended study protocol (see BioCentury, Jan. 2). ...